Navigation Links
As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
Date:2/23/2009

Percentage of Clinicians Performing hsCRP Testing Will Increase Dramatically Over the Next Six Months, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, as a result of the JUPITER clinical trial, 65 percent of surveyed managed care organizations' (MCO) pharmacy directors say they will reimburse AstraZeneca's Crestor for healthy patients with elevated levels of high sensitivity C-reactive protein (hsCRP). The JUPITER trial enrolled apparently healthy subjects without high LDL cholesterol but with elevated hsCRP and randomized subjects to receive Crestor or placebo. Trial data showed a 44 percent reduction in major cardiovascular events and reduced all-cause mortality by 20 percent among participants receiving Crestor.

The new Physician & Payer Forum report entitled The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? finds that 15 percent of surveyed MCO pharmacy directors will grant Crestor more favorable tier status in light of the trial. Crestor is currently on tier one of only 10 percent of surveyed MCO private health plans, while Pfizer's Lipitor is on tier one of 30 percent of surveyed MCO plans. Additionally, among Medicare prescription drug plans, Crestor has the highest rate of coverage among branded statins.

"Our findings suggest that in response to the JUPITER trial data, many clinicians will start using a statin ahead of diet and exercise changes," said Decision Resources Analyst Graeme Green, Ph.D. "Most of these clinicians will favor Crestor for these patients, indicating that AstraZeneca will benefit the most from such a trend."

The report finds that, in response to JUPITER trial data, the percentage of clinicians performing hsCRP testing will increase dramatically over the next six months among patients with and without cardiovascular risk factors. Surveyed clinicians anticipate that the percentage of patients with no cardiovascular risk factors tested for elevated hsCRP will increase from 5 percent in July 2008, to 26 percent in July 2009. The percentage of patients with two or more cardiovascular risk factors tested by primary care physicians for hsCRP will increase from 16 percent in July 2008 to 40 percent in July 2009.

The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? is based on a U.S. survey of 71 primary care physicians, 72 cardiologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                           Decision Resources, Inc.
    Christopher Comfort                          Elizabeth Marshall
    781-296-2597                                 781-296-2563
    ccomfort@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
2. XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
3. Insulet Corporation to Report Fourth Quarter and Full Year 2008 Financial Results on Thursday, March 5, 2009
4. WebMD Announces Fourth Quarter Financial Results
5. Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
6. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
7. HLTH Corporation Announces Fourth Quarter Financial Results
8. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
9. Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Fourth Quarter 2008 Earnings Results Webcast
10. QLT Announces Fourth Quarter and Year End 2008 Results
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... For many women, getting birth control isn’t as easy as it should be. In fact, ... to a health care facility or a pharmacy within 60 minutes of where they live. ... for many who are faced with health or personal issues that leave them homebound. To ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to be invited to the Siemens Healthineers annual customer education symposium, a world-class ... will take place from March 27 - 31, 2017 at the Atlanta Marriott ...
(Date:3/28/2017)... ... ... Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of the world, is ... about journey and research recently on a blog and discussed some major aspects of ... deal with thyroid disease. , Dr. Wentz completed her graduation from the Midwestern ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... medical society dedicated to advancing the science and clinical practice of radiosurgery, ... RSSearch Patient Registry, a multi-institutional, observational registry established to standardize data collection ...
(Date:3/28/2017)... ... 28, 2017 , ... Z-Medica, LLC, a leading developer and ... (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 ... efforts by the American College of Surgeons, U.S. Department of Defense, Department of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... CITY, Calif. , March 28, 2017 /PRNewswire/ ... company focused on the development and commercialization of ... pain, announced that the European Medicines Agency (EMA) ... sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) ... of the MAA is underway. The MAA for ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
Breaking Medicine Technology: